Seralutinib is an investigational, inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and mast/stem cell growth factor receptor kit (c-KIT). It was intentionally designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler.
Seralutinib is currently being evaluated in a phase 3 clinical trial for the treatment of pulmonary arterial hypertension (PAH). Additionally, Gossamer Bio expects to initiate a global phase 3 registrational clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) mid-2025.
Seralutinib Clinical Development
| Indication | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
| PAH | |||
| PH-ILD | Ph 3 initiation expected mid-2025 | ||
| Phase 1 | Phase 2 | Phase 3 |
| PAH | ||
| PH-ILDPh 3 initiation expected mid-2025 | ||
